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ABSTRACT
Methotrexate (MTX) has been used in combination with non-
steroidal anti-inflammatory drugs (NSAIDs) in the treatment of
inflammatory diseases as well as malignancies. Especially at
high MTX dosages, severe adverse effects with this combina-
tion may occur, usually resulting from an impaired renal elimi-
nation. It has been shown that the mechanism of this interac-
tion cannot be fully attributed to inhibition of basolateral MTX
uptake in renal proximal tubules. Here, we studied the effect of
various NSAIDs on MTX transport in membrane vesicles iso-
lated from cells overexpressing the proximal tubular apical
efflux transporters human multidrug resistance protein (MRP)
2/ABCC2 and MRP4/ABCC4. MTX was transported by MRP2
and MRP4 with Km values of 480  90 and 220  70 M,
respectively. The inhibitory potency of the NSAIDs was gener-
ally higher against MRP4- than MRP2-mediated MTX transport,
with therapeutically relevant IC50 values, ranging from approx-
imately 2 M to 1.8 mM. Salicylate, piroxicam, ibuprofen,
naproxen, sulindac, tolmetin, and etodolac inhibited MRP2-
and MRP4-mediated MTX transport according to a one-site
competition model. In some cases, more complex interaction
patterns were observed. Inhibition of MRP4 by diclofenac and
MRP2 by indomethacin and ketoprofen followed a two-site
competition model. Phenylbutazone stimulated MRP2 and
celecoxib MRP4 transport at low concentrations and inhibited
both transporters at high concentration. Our data suggest that
the inhibition by NSAIDs of renal MTX efflux via MRP2 and
MRP4 is a potential new site and mechanism contributing to the
overall interaction between these drugs.
Methotrexate (MTX) has been successfully used for more
than three decades in treating various malignant tumors and
autoimmune disorders. Although MTX is generally well tol-
erated, unpredictable life-threatening toxicity still occurs at
high dosages or concomitant use with other drugs, resulting
in persistently high plasma concentrations. Of the drugs
causing such interactions with MTX, nonsteroidal anti-in-
flammatory drugs (NSAIDs) have been well known (Kremer
and Hamilton, 1995). Numerous clinical case reports have
documented that NSAIDs can cause a reduction in the MTX
clearance, even at relatively low maintenance dosages used
to treat rheumatoid arthritis. Ketoprofen, indomethacin, and
diclofenac caused different levels of toxicities in patients
receiving MTX, ending fatally in three of four patients re-
ceiving ketoprofen (Thyss et al., 1986), two of which had
approximately 12-fold higher MTX serum levels. Similar tox-
icities were found with salicylate (Stewart et al., 1991), ibu-
profen (Cassano, 1989), and naproxen (Singh et al., 1986).
MTX is primarily excreted into urine in the unchanged
form, and renal handling involves tubular secretion and re-
absorption, in addition to glomerular filtration. Renal tubu-
lar secretion of MTX has been thought to be a major site of
interaction with other drugs (Takeda et al., 2002). The first
step is active uptake from the blood across the basolateral
membrane into the proximal tubular cells via the organic
anion transporters (OATs) 1 and 3 and the reduced folate
carrier-1 (Nozaki et al., 2004). Extrusion from the cells across
the luminal membrane into the urine is mediated by the
ATP-dependent efflux pumps, multidrug resistance proteins
(MRPs) 2 and 4 (Masuda et al., 1997; Chen et al., 2002; van
Aubel et al., 2002). Furthermore, MTX is recognized by lu-
minal OAT4 (Takeda et al., 2002), which reabsorbs anions
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from the primary urine back into the tubular cells (Ekara-
tanawong et al., 2004). The interaction of NSAIDs with MTX
uptake at the basolateral membrane has been investigated
recently, and the results showed that several NSAIDs inhib-
ited MTX uptake via human OAT1 and OAT3 at clinically
relevant concentrations (Takeda et al., 2002). Nevertheless,
when studied in rat kidney slices, the interaction was not as
potent as presumed, probably because reduced folate carri-
er-1, which is insensitive to NSAIDs, also contributes signif-
icantly to tubular MTX uptake (Nozaki et al., 2004). To date,
the effect of NSAIDs on the luminal efflux of MTX via MRP2
and MRP4 has not yet been studied as potential site of this
drug-drug interaction.
The expression of MRP2 (Schaub et al., 1997) and MRP4
(van Aubel et al., 2002) in the kidney is restricted to the
luminal membrane of the proximal tubule cells. Mutations in
the gene encoding MRP2 (ABCC2) causing Dubin-Johnson
syndrome, a rare form of conjugated hyperbilirubinemia, can
impair high-dose MTX elimination, leading to renal toxicity
in vivo (Hulot et al., 2005). Previous studies showed that
MRP4-mediated estradiol 17--D-glucuronide transport was
inhibited potently by several NSAIDs (Reid et al., 2003),
suggesting that these drugs might be potential inhibitors of
other MRP4 substrates. In addition, luminal efflux trans-
porters may get exposed to relatively high inhibitor concen-
trations because NSAIDs can be taken up actively into the
proximal tubular cells via basolateral OATs (Sekine et al.,
1997; Apiwattanakul et al., 1999). The objective of this study
was to investigate the interaction potential of NSAIDs with
the renal MTX efflux transporters MRP2 and MRP4. For this
purpose, we used membrane vesicles isolated from cells over-
expressing human MRP2 and MRP4. Our findings show that
various NSAIDs inhibit both MRP2- and MRP4-mediated
MTX transport, in general with higher inhibitory potency
against MRP4. Our study also shows different and some-
times complex inhibitory patterns of the various NSAIDs
tested. This is the first study in which this putative drug-
drug interaction is examined at the molecular level.
Materials and Methods
Materials. [3,5,7-3H(n)]MTX sodium salt (51.5 Ci/mmol) was
purchased from Moravek Inc. (Brea, CA). The Bac-to-Bac and Gate-
way system were purchased from Invitrogen (Breda, The Nether-
lands). Creatine phosphate and creatine kinase were purchased from
Roche Diagnostics (Almere, The Netherlands). NC45 filters were
obtained from Schleicher and Schuell (Den Bosch, The Netherlands).
Protein concentrations were determined with an assay kit form
Bio-Rad Laboratories (Veenendaal, The Netherlands). Celecoxib was
purified from 200-mg Celebrex capsules, Pfizer (Capelle a/d Ijssel,
The Netherlands) according to a previously described method (Tong
et al., 2005).
Cell Lines and Culture Conditions. The MRP2-overexpressing
MDCKII cell line was kindly provided by Dr. P. Borst (Dutch Cancer
Institute, Amsterdam, The Netherlands) and was cultured as de-
scribed previously (Evers et al., 1998). The nontransfected MDCKII
cell line was used as a control. HEK293 cells were grown in DMEM
supplemented with 10% fetal calf serum at 37°C under 5% CO2-
humidified air.
Generation of Human MRP4 Baculovirus. The Bac-to-Bac
system, normally used for protein production in insect cells, was
made suitable for protein expression in mammalian cells by cloning
the vesicular stomatitis virus G protein cDNA behind the P10 pro-
moter of the pFastBacDual vector. Next, the CMV promoter and
Gateway destination elements (cassette that contains the chloram-
phenicol resistance gene and the ccdB gene flanked by attR1 and
attR2 sites) were introduced in the pFastBacDual vector. The human
MRP4 was cloned into the Gateway entry vector. The sequence of
this MRP4 construct is equal to GenBank accession number
NM_005845 except for the I18L polymorphism. This MRP4 cDNA
was transferred to the newly constructed Bac-to-Bac vector with the
gateway LR reaction. Baculoviruses were produced as described in
the Bac-to-Bac manual. As a control, the enhanced yellow fluorescent
protein was also cloned into the gateway entry vector (Invitrogen).
Transduction of HEK293 Cells. HEK293 cells were cultured in
182-cm2 flasks until 70% confluence, after which the culture medium
was removed and 1.5 ml of virus and 3.5 ml of medium were added.
The cells were incubated for 30 to 60 min at 37°C, after which 20 ml
of medium was added. After 24 h of transduction, sodium butyrate (5
mM) was added. Three days after transduction, the cells were har-
vested.
Isolation of Membrane Vesicles and Protein Analysis. Cells
were harvested by centrifugation at 3000g for 30 min. The pellets
were resuspended in ice-cold homogenization buffer (0.5 mM sodium
phosphate, 0.1 mM EDTA, pH 7.4) supplemented with protease
inhibitors (100 M phenylmethylsulfonyl fluoride, 5 g/ml aprotinin,
5 g/ml leupeptin, 1 M pepstatin, and 1 M E-64) and shaken at
4°C for 60 min. Lysed cells were centrifuged at 4°C at 100,000g for 30
min, and the pellets were homogenized in ice-cold TS buffer (10 mM
Tris-HEPES and 250 mM sucrose, pH 7.4) using a tight fitting
Dounce homogenizer for 30 strokes. After centrifugation at 500g at
4°C for 20 min, the supernatant was centrifuged at 4°C at 100,000g
for 60 min. The resulting pellet was resuspended in TS buffer and
passed through a 27-gauge needle 30 times. Protein concentration
was determined by a Bio-Rad protein assay kit. Crude membrane
vesicles were dispensed in aliquots, frozen in liquid nitrogen, and
stored at 80°C until use.
Immunoblotting. The membrane vesicle preparations were di-
luted in TS buffer. The indicated amount of protein was size frac-
tionated on a 7.5% SDS-polyacrylamide gel and subsequently blotted
on nitrocellulose membrane. Affinity-purified, polyclonal anti-hu-
man MRP2 (pAb hM2-p1) and anti-human MRP4 (pAb hM4-p4)
antibodies (1:1000) were used to detect human MRP2 and MRP4,
respectively (van Aubel et al., 2002; Smeets et al., 2004). Signals
were visualized with chemiluminescence (Amersham Biosciences,
Diegem, Belgium).
Vesicular Transport Assays. Uptake of [3H]MTX into mem-
brane vesicles was performed as described previously (van Aubel et
al., 1999). In brief, membrane vesicles were prewarmed for 1 min at
37°C and added to TS buffer, supplemented with an ATP-regenera-
tion mixture (4 mM ATP, 10 mM MgCl2, 10 mM creatine phosphate,
and 100 mg/ml creatine kinase) in a final volume of 60 l. The
reaction mixture was incubated at 37°C for 15 min, and samples
were taken from the mixture at indicated times, diluted in 900 l of
ice-cold TS buffer. Diluted samples were filtered through 0.45-m-
pore NC filters that were preincubated with TS buffer by a filtration
device (Millipore, Bedford, MA) using a rapid filtration method. After
adding 4 ml of scintillation fluid and subsequent liquid scintillation
counting, uptake of [3H]MTX into membrane vesicles was studied by
measuring radioactivity associated with the filters.
In control experiments, ATP was substituted with AMP. Net ATP-
dependent transport was calculated by subtracting values measured
in the presence of AMP from those measured in the presence of ATP.
Measurements were corrected for the amount of ligand bound to the
filters (usually 2% of total radioactivity). Each experiment was
performed in triplicate. The sidedness of the membrane vesicles was
not determined. ATP-dependent uptake can only occur in inside-out
vesicles, and because inhibition by NSAIDs is expressed relatively as
percentage of MTX uptake, the result is not affected by differences in
expression levels and sidedness of the vesicles.
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Transport Inhibition Assays. To evaluate the inhibitory effects
of NSAIDs on MTX uptake mediated by MRP2 and MRP4, the
previously mentioned transport assay was performed using 0.5 M
[3H]MTX, in the absence or presence of various concentrations of
NSAIDs. Hydrophilic NSAIDs, viz. salicylate, diclofenac, tolmetin,
ibuprofen, and naproxen, were dissolved in H2O. Hydrophobic
NSAIDs, viz. sulindac, indomethacin, etodolac, ketoprofen, phenyl-
butazone, piroxicam, and celecoxib, were dissolved in dimethyl sul-
foxide (DMSO) and diluted with incubation medium.
The final concentration of DMSO in the incubation medium was
adjusted to less than 1% (Apiwattanakul et al., 1999). We tested the
effect of 1% DMSO and observed a reduction of approximately 20% in
transport. Because in all transport assays the same concentration of
DMSO was used as a control, this reduction did not influence the
results. In all experiments with hydrophobic NSAIDs, control sam-
ples contained the same concentration of DMSO.
Kinetic Analysis. All data were expressed as means  S.E. IC50
values of NSAIDs were obtained from curve fitting of the resulting
concentration-inhibition curves by nonlinear regression analysis us-
ing GraphPad Prism software version 4.03 (GraphPad Software Inc.,
San Diego, CA). Statistical differences were determined using a
one-way analysis of variance with Dunnett’s post test. Differences
were considered to be significant at P  0.05.
Results
Expression of MRP2 and MRP4 in Isolated Mem-
brane Vesicles. Immunoblot analysis was performed on
membrane vesicles prepared from MDCKII and HEK293
cells overexpressing human MRP2 and MRP4, respectively.
Figure 1 demonstrates that both MRP2 and MRP4 were
successfully expressed and were detected as 190-kDa
(Schaub et al., 1999; van Aubel et al., 2002) and 170-kDa (Lee
et al., 2000; van Aubel et al., 2002) bands, respectively,
whereas control MDCKII and HEK293 vesicles did not show
any protein expression at the corresponding heights.
Time-Dependent Uptake of MTX by MRP2 and
MRP4. Membrane vesicles were incubated for 2.5, 5, 10, 15,
20, and 30 min at 37°C in uptake medium containing 0.5 M
[3H]MTX. A relatively low MTX concentration was chosen
because the specific activity of the radiolabel was not very
high and for an accurate determination of IC50 values, a
substrate concentration well below the Km must be used. The
relative contribution of MRP2 or MRP4 to overall uptake was
assessed in parallel experiments performed on membrane
vesicles isolated from control MDCKII and HEK293 cells,
respectively. Both MRP2 and MRP4 mediated ATP-depen-
dent [3H]MTX transport (Fig. 2). Transport of [3H]MTX in-
creased with time, and the uptake was linear over the first 20
min of the assay for both MRP2 and MRP4. Uptake at 20 min
remained linear up to the highest [3H]MTX concentrations
used in the experiments to assess the concentration depen-
dence of transport, viz. 2 mM for MRP2 and 1 mM for MRP4
vesicles (data not shown).
Concentration-Dependent Transport of MTX by
MRP2 andMRP4.Membrane vesicles were incubated for 15
min at 37°C with 3H-labeled and unlabeled MTX to the final
concentrations indicated (Fig. 3). ATP-dependent transport
was calculated by subtracting the values obtained in the
presence of AMP from those in the presence of ATP. MRP2-
and MRP4-dependent uptakes were calculated by subtract-
ing nonspecific uptakes in control MDCKII and HEK293
vesicles, respectively. MRP2 and MRP4 efficiently trans-
ported MTX, and the concentration of MTX at half-maximal
uptake rates (Km) was relatively higher for MRP2 than for
MRP4. The Km and Vmax values for MTX uptake in MRP2
and MRP4 vesicles were 480 90 and 220 70 M and 80
10 and 280  30 pmol/mg/min, respectively. It should be
noted that because of different expression systems, the en-
richment of the transporters may be different, and therefore,
it is only meaningful to compare Km values.
Effect of NSAIDs on MRP2- and MRP4-Mediated
MTX Transport. Membrane vesicles were incubated with
0.5 M [3H]MTX at 37°C for 15 min in the absence or pres-
ence of increasing concentrations of the various NSAIDs
(Figs. 4 and 5). All NSAIDs studied inhibited MRP2- and
MRP4-mediated MTX transport with different potencies and
sometimes complex kinetic interactions. The calculated IC50
values are given in Table 1. Figure 4 shows that salicylate
inhibited MTX transport with nearly the same IC50 values
for MRP2 and MRP4 and with the lowest inhibitory potency
of all the NSAIDs tested (Table 1). Piroxicam gave a similar
inhibitory pattern, whereas the inhibitory potency of ibupro-
fen, naproxen, sulindac, and tolmetin was significantly
higher against MRP4- than MRP2-mediated MTX transport.
Figure 5 shows that etodolac was the only NSAID that
gave a steep inhibition curve of MRP2-mediated MTX trans-
port, with a slope factor significantly higher than one. Fur-
thermore, the inhibitory pattern of diclofenac on MRP4-me-
diated transport and of indomethacin and ketoprofen on
MRP2-mediated MTX transport could not be simply de-
scribed according to a one-site competition model but was
fitted significantly better using the two-site model. Phenyl-
butazone produced a bell-shaped curve against MRP2- but
Fig. 1. Immunoblot analysis of MRP2 and MRP4 expression in mem-
brane vesicles used for transport studies. Membrane vesicles were pre-
pared from control MDCKII and HEK293 as well as cells overexpressing
human MRP2 and MRP4, respectively.
Fig. 2. Time-dependent uptake of [3H]MTX in MRP2 and MRP4 mem-
brane vesicles. Vesicles were incubated for 2.5, 5, 10, 15, 20, and 30 min
at 37°C in uptake medium containing 0.5 M [3H]MTX. ATP-dependent
[3H]MTX uptake was calculated by subtracting uptake in the presence of
AMP from uptake in the presence of ATP in membrane vesicles from
control (▫) or MRP2-expressing (f) MDCKII cells and control (E) or
MRP4-expressing (F) HEK293 cells. Data present mean and S.E. of at
least three different experiments, each performed in triplicate.
NSAIDs Inhibit MTX Transport by MRP2 and MRP4 231
 at R
adboud Universiteit Nijmegen on July 11, 2012
jpet.aspetjournals.org
D
ow
nloaded from
 
not MRP4-mediated transport, with significant stimulation
up to 170  16% at low and inhibition at higher concen-
trations. Celecoxib, the only selective cyclooxygenase II
inhibitor tested, showed a mild but statistically significant
stimulation of MRP4-mediated MTX transport at low
concentrations. In contrast to what has been described by
others (Zelcer et al., 2003), we could not find a stimulatory
effect of indomethacin on MRP2-mediated MTX transport.
Fig. 4. Effect of salicylate, piroxicam,
ibuprofen, naproxen, sulindac, and
tolmetin on MRP2- and MRP4-medi-
ated [3H]MTX uptake in membrane
vesicles. Vesicles were incubated with
0.5 M [3H]MTX at 37°C for 15 min,
in the absence or presence of increas-
ing concentrations of the NSAIDs
tested. Uptake was measured by sub-
tracting the background (AMP) from
the ATP-dependent uptake. Respec-
tive [3H]MTX transport rates for
MRP2 () and MRP4 (F) were ex-
pressed as a percentage of control up-
take against the log NSAID concen-
tration. Data present mean and S.E.
of three different experiments, each
performed in triplicate.
Fig. 3. Concentration-dependent uptake of [3H]MTX in MRP2 and MRP4 membrane vesicles. Vesicles were incubated for 15 min at 37°C with
3H-labeled and unlabeled MTX to the final concentrations indicated in the figure. ATP-dependent uptake is measured by subtracting uptake in the
presence of AMP from that measured in the presence of ATP. ATP-dependent uptake of MTX by MRP2 () and MRP4 (F) was determined after
subtraction of ATP-dependent uptake in the corresponding control vesicles fromMDCKII and HEK293 cells, respectively. Data present mean and S.E.
of at least three different experiments, each performed in triplicate.
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Discussion
Severe and sometimes fatal side effects have been observed
in patients after the coadministration of MTX and NSAIDs.
To date the specific mechanisms contributing to this interac-
tion have not been fully identified. It has been shown that
inhibition of basolateral MTX uptake in renal proximal tu-
bules via OAT1 and 3 is an important site of competition with
NSAIDs but not as powerful to account for the full interac-
tion. In the present study, we show that a wide variety of
NSAIDs inhibited MRP2- and MRP4-mediated MTX trans-
port at concentrations to which the transporters may be
exposed under therapeutic conditions, adding a new possible
site and mechanism to the overall MTX-NSAID interaction.
Although all NSAIDs tested are weak organic acids, they
are chemically diverse and possess a wide range of pharma-
cokinetic characteristics, which makes it difficult to study the
relationship between structure and inhibitory activity. In our
study, sulindac had the highest and salicylate the lowest
inhibitory potency for both MRP2 and MRP4. Etodolac was
the only NSAID tested with an inhibitory curve with a slope
factor significantly higher than unity, indicating positive co-
operativity in inhibition. Most NSAIDs had a higher inhibi-
tory potency against MRP4- than MRP2-mediated transport.
The effect of diclofenac on MRP4 and of indomethacin and
ketoprofen on MRP2 exhibited a two-site competition model.
Furthermore, phenylbutazone and celecoxib showed a dual
effect. At low concentrations, phenylbutazone had a strong
stimulatory effect on MTX transport via MRP2 but not
MRP4, whereas celecoxib stimulated MRP4 transport mod-
estly. At higher concentrations, phenylbutazone and cele-
coxib inhibited both transporters. This is compatible with the
suggestion that both MRP2 (Zelcer et al., 2003) and MRP4
(van Aubel et al., 2005) have more than one binding site. This
phenomenon was previously explained by the existence of
two independent binding sites, one site that transports sub-
strates and another site that can allosterically modulate the
substrate transport site (Zelcer et al., 2003). Compounds that
can stimulate as well as inhibit transport probably bind at
low concentrations preferentially to the modulatory site,
whereas at high concentrations, they can also compete for the
Fig. 5. Effect of etodolac, diclofenac,
indomethacin, ketoprofen, celecoxib,
and phenylbutazone on MRP2- and
MRP4-mediated [3H]MTX uptake in
membrane vesicles. Vesicles were in-
cubated with 0.5 M [3H]MTX at 37°C
for 15 min in the absence or presence
of different concentrations of the
NSAIDs tested. Uptake was mea-
sured by subtracting the background
(AMP) from the ATP-dependent up-
take. Respective [3H]MTX transport
rates for MRP2 () and MRP4 (F)
were expressed as a percentage of con-
trol uptake against the log NSAID
concentration. Data present mean
and S.E. of three different experi-
ments, each performed in triplicate.
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substrate transport site. This type of allosteric interaction
seems a common characteristic of the MRPs.
Several NSAIDs belonging to the selective cyclooxygenase
II inhibitors were reported not to affect the clinical pharma-
cokinetics of MTX (Schwartz et al., 2001; Hartmann et al.,
2004), including celecoxib (Karim et al., 1999). This may be
due to the low immunosuppressive MTX dosages used in
these studies. Our results show that celecoxib can be a potent
inhibitor of MRP2- and MRP4-mediated renal MTX efflux.
The MTX concentration of 0.5 Mwe used in the inhibition
experiments is relatively low as compared with plasma con-
centrations after therapeutic dosages, which are highly vari-
able and may range from 0.1 up to 20 to 50 M. Because of
tubular accumulation of MTX via active uptake, it is likely
that intracellular concentrations will exceed the plasma con-
centration. Apparently, MRP4 transports MTX with higher
affinity than MRP2. Previous studies reported that Km val-
ues of MTX were higher for MRP2 (2.5–3 mM) (Bakos et al.,
2000) than for MRP4 (0.22–1.3 mM) (Chen et al., 2002; van
Aubel et al., 2002), which is in line with our results. In
addition, the protein expression of MRP4 is 5-fold higher
than MRP2 in human kidney cortex (Smeets et al., 2004).
Furthermore, by comparing the IC50 values of different
NSAIDs, we found that NSAIDs generally exhibited a higher
inhibitory potency against MRP4. Given this information, we
would expect that MRP4 plays a more important role than
MRP2 in the inhibition of renal MTX efflux by NSAIDs. On
the other hand, a recent study in Mrp2/ mice showed
1.8-fold higher plasma concentrations of MTX as compared
with wild-type mice. Although Mrp4 expression was in-
creased 2-fold in the knockouts, apparently it was not able to
compensate for the loss of Mrp2 in these mice (Vlaming et al.,
2006). Furthermore, it was reported that in a patient with
MRP2 protein dysfunction caused by a genetic variation in
the MRP2/ABCC2 gene, MTX excretion was impaired, lead-
ing to severe overdose manifestations as nephrotoxicity,
amounting to renal failure (Hulot et al., 2005). The apparent
contradiction between the expected higher effects of MRP4
participating in MTX elimination at the molecular level
needs further investigation. It is hard to define the relative
influence of a certain NSAID on the urinary excretion of
MTX, making it very difficult to recommend a specific NSAID
with the lowest interaction potential in patients. In addition
to the inhibitory potency of the NSAIDs, a number of other
factors should be taken into consideration: the variation in
NSAID dosing, which, in case of salicylate, may reach gram
quantities per day producing serum concentration ranging
from several hundred micromolars to several millimolars
(Cerletti et al., 2003), the concentration of unchanged
NSAIDs reached in proximal tubular cells by carrier-medi-
ated uptake, and the possible effects of NSAID metabolites
on MTX efflux. Because of extensive plasma protein binding
ranging from 90 to 99%, the unbound concentrations of
NSAIDs in plasma are low. The estimated unbound thera-
peutic concentration of the most potent inhibitors, sulindac
and indomethacin, are approximately 1 and 8 M, respec-
tively, which is in the range of their IC50 values for MRP4
(Davies and Skjodt, 2000; Takeda et al., 2002; Chen et al.,
2006). For the other NSAIDs tested, unbound plasma con-
centrations are considerably lower than their IC50 values,
but it should be noticed that some of these compounds are
also actively taken up in the proximal tubular cells by or-
ganic anion transporters, resulting in much higher concen-
trations to which MRP2 and MRP4 will be exposed (Apiwat-
tanakul et al., 1999).
In summary, our study shows that MRP2- and MRP4-
mediated efflux of MTX can be inhibited by various NSAIDs
at therapeutically relevant concentrations. Because MRP2
and MRP4 are important efflux transporters for MTX in the
kidney, they are potential new sites of MTX-NSAIDs inter-
action. The relative contribution of this mechanism to the
overall inhibition of renal MTX excretion by NSAIDs and the
individual roles of MRP2 and MRP4 herein need to be estab-
lished in future in vivo studies.
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